Secukinumab Retention High in Real-World Study of Patients With PsA, AxSpA – AJMC.com Managed Markets Network
A new real-world research study evaluates the safety profile and discontinuation rates of Cosentyx (secukinumab) in patients with axial spondyloarthritis (AxSpA) and psoriatic arthritis (PsA) CONTEXT: This report published in Continue Reading